



CERTIFICATE OF LISTING OF IDENTICAL PRODUCT

Pursuant to the provisions of Republic Act (R.A.) No. 3720 as amended, known as the Foods, Drugs, Devices and Cosmetics Act, and consistent with R.A. No. 6675, known as the Generics Act of 1988, and R.A. No. 9711, otherwise known as the Food and Drug Administration Act of 2009, the product described hereunder has been found to conform with the requirements and standards for marketing authorization of pharmaceutical products per existing regulations in force as of date hereof.

Registration Number : **DRP-6357-06**
Generic Name : Co-Amoxiclav
Brand Name : Cozeal
Dosage Strength & Form : 875 mg/125 mg Film-Coated Tablet
Pharmacologic Category : Antibacterial (Penicillin-Beta-Lactamase Inhibitor Combination)
Classification : Prescription Drug (Rx)
Approved Shelf-life : 24 months
Storage Condition : Store at temperatures not exceeding 30°C
Packaging : Alu/Foil Strip x 7's (Box of 14's)
Manufacturer : Pil Pharmaceuticals Pvt. Ltd.
Plot No. 71-72, Sector-6A, IIE, SIDCUL, Ranipur,
District-Haridwar, 249403 Uttarakhand, India
Importer : JF Draf Pharmaceuticals Corp.
Suite 407, Greenhills Mansion, 37 Annapolis St., North
East Greenhills, San Juan, Metro Manila
Distributor : Pharmasilv Trading
B4 L11 #19 Executive Homes 1, Cainta Greenpark Vill,
San Isidro, Cainta, Rizal

The Certificate of Listing issued to the above Distributor shall be valid until **02 October 2025**, which covers the unexpired term of the Principal CPR, subject to the conditions listed on the reverse side. No change in the ownership, registrant's address/location, manufacturer, excipients, formulation, dosage form, strength, therapeutic indication, manufacturing process, labelling and commercial presentation, and packaging of the Principal product covered by the Principal CPR without prior approval of this Office.

This Certificate of Listing is subject to suspension, cancellation or recall should any violation of R.A. No. 3720, R.A. No. 6675 and R.A. No. 9711 and/or regulations issued thereunder involving the product be committed.

Witness My Hand and Seal of this Office, this **04 May 2021**.

By Authority of the Director General
Per FDA Order No. 2016-005

JESUSA JOYCE N. CIRUNAY, RPh

Director IV
Center for Drug Regulation and Research

REG. STATUS : Automatic Renewal
AMOUNT : Php 2,020.00; Php 8,080.00
OR NUMBER : SEQ#100120181332; SEQ#31021250850
DATE : 01 October 2020; 10 March 2021

BAR CODE
DOC TRACK



2 0 2 0 0 9 3 0 1 4 5 5 2 3



FDA-0510663

Registration Number : DRP-6357-06

SPECIAL CONDITION:

Provided that nothing in the registration of the product herein granted shall be interpreted or construed as an endorsement or representation by FDA, that Registrant has the right or privilege to the use of the name or brand so registered; Registrant hereby agrees and affirms to indemnify and/or hold FDA free and harmless against any and all third-party claims on infringement of patent, trademark or intellectual property right arising from the registration of the product.

- | | | |
|-------------------------------------|----------|---|
| <input checked="" type="checkbox"/> | A | This is subject to batch notification. |
| <input type="checkbox"/> | B | This is subject to lot release certification. |
| <input type="checkbox"/> | C | This is subject to compliance with the requirements under FDA Circular No. 2013-004 for drug products under Monitored Release (MR) registration. |
| <input checked="" type="checkbox"/> | D | Subject to post-marketing surveillance of the marketing authorization holder's strict compliance to the Generic Labeling Requirements following the applicable provisions of A.O No. 2016-0008 for drug products for human use and A.O. No. 105 s. 1991 for veterinary drug products. |
| <input checked="" type="checkbox"/> | E | Submit a satisfactory Bioequivalence Study Report or Biowaiver (whichever is applicable) within the validity of this CPR in accordance with FDA Circular No. 2016-019. |
| <input type="checkbox"/> | F | Dangerous Drug - To be prescribed by PDEA S-2 licensed practitioner in a DOH (yellow) prescription form. It is a habit-forming drug. |
| <input type="checkbox"/> | G | Dangerous Drug - To be prescribed by PDEA S-2 licensed practitioner in a personalized ordinary prescription. It is a habit-forming drug. |
| <input type="checkbox"/> | H | Patient Information Leaflet - Appropriate information for the consumers shall be written in Filipino and/or local dialect(s), as appropriate. |
| <input type="checkbox"/> | I | Submit a Certificate of Good Manufacturing Practice (GMP) Compliance of Foreign Drug Manufacturer(s) within the validity of this CPR in accordance with A. O. 2013-0022 and FDA Circular 2014-016. |
| <input type="checkbox"/> | J | Review of the submitted Bioequivalence Study Report or Biowaiver, whichever is applicable, shall be completed by the FDA within the validity of this CPR; correspondingly, this CPR shall be revoked if product interchangeability has not been established. |
| <input type="checkbox"/> | K | Subject to satisfactory compliance to the post-approval commitments detailed in the letter accompanying this CPR. |

REMARKS:

This Certificate of Listing of Identical Drug Product (CLIDP) is granted following Department Circular 2011-0101: The Rules and Regulations Implementing Republic Act No. 9711 - The Food and Drug Administration Act of 2009.